Subhiksha Nandakumar
YOU?
Author Swipe
View article: EPCO-51. GENOMIC FEATURES OF DIFFUSE MIDLINE GLIOMAS IN PEDIATRIC PATIENTS, YOUNG ADULTS, AND ADULTS: A RETROSPECTIVE COHORT STUDY
EPCO-51. GENOMIC FEATURES OF DIFFUSE MIDLINE GLIOMAS IN PEDIATRIC PATIENTS, YOUNG ADULTS, AND ADULTS: A RETROSPECTIVE COHORT STUDY Open
Diffuse midline glioma (DMG) is the second most common malignant pediatric brain tumor, occurring predominantly in children 3–10 years old. Recent studies suggest considerable epigenetic, genomic, and clinical diversity within this entity.…
View article: BRCA2 reversion mutation–independent resistance to PARP inhibition through impaired DNA prereplication complex function
BRCA2 reversion mutation–independent resistance to PARP inhibition through impaired DNA prereplication complex function Open
Recent approvals of polymeric adenosine diphosphate ribose (poly(ADP-ribose) polymerase inhibitors (PARPi) for BRCA-mutant metastatic castration resistant prostate cancer necessitate an understanding of the factors that shape sensitivity a…
View article: BCL2 drives castration resistance in castration-sensitive prostate cancer by orchestrating reciprocal crosstalk between oncogenic pathways
BCL2 drives castration resistance in castration-sensitive prostate cancer by orchestrating reciprocal crosstalk between oncogenic pathways Open
View article: BRCA2 reversion mutation-independent resistance to PARP inhibition in prostate cancer through loss of function perturbations in the DNA pre-replication complex
BRCA2 reversion mutation-independent resistance to PARP inhibition in prostate cancer through loss of function perturbations in the DNA pre-replication complex Open
Recent approvals of PARP inhibitors (PARPi) for BRCA-mutant metastatic castration resistant prostate cancer (mCRPC) necessitate an understanding of the factors that shape sensitivity and resistance. Reversion mutations that restore homolog…
View article: Sharing data from the Human Tumor Atlas Network through standards, infrastructure and community engagement
Sharing data from the Human Tumor Atlas Network through standards, infrastructure and community engagement Open
View article: Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival
Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival Open
View article: Maximizing the clinical utility and performance of cytology samples for comprehensive genetic profiling
Maximizing the clinical utility and performance of cytology samples for comprehensive genetic profiling Open
Comprehensive molecular profiling by next-generation sequencing has revolutionized tumor classification and biomarker evaluation. However, routine implementation is challenged by the scant nature of diagnostic material obtained through min…
View article: Automated real-world data integration improves cancer outcome prediction
Automated real-world data integration improves cancer outcome prediction Open
View article: Real-world experience with circulating tumor DNA in cerebrospinal fluid from patients with central nervous system tumors
Real-world experience with circulating tumor DNA in cerebrospinal fluid from patients with central nervous system tumors Open
View article: Data from A Phase II Study Assessing Long-term Response to Ibrutinib Monotherapy in Recurrent or Refractory CNS Lymphoma
Data from A Phase II Study Assessing Long-term Response to Ibrutinib Monotherapy in Recurrent or Refractory CNS Lymphoma Open
Purpose:Ibrutinib is a first-in-class inhibitor of Bruton tyrosine kinase. We previously reported the safety and short-term antitumor activity of ibrutinib in 20 patients with relapsed or refractory (r/r) primary central nervous system (CN…
View article: Supplementary Data 1 from A Phase II Study Assessing Long-term Response to Ibrutinib Monotherapy in Recurrent or Refractory CNS Lymphoma
Supplementary Data 1 from A Phase II Study Assessing Long-term Response to Ibrutinib Monotherapy in Recurrent or Refractory CNS Lymphoma Open
Additional data
View article: Data from A Phase II Study Assessing Long-term Response to Ibrutinib Monotherapy in Recurrent or Refractory CNS Lymphoma
Data from A Phase II Study Assessing Long-term Response to Ibrutinib Monotherapy in Recurrent or Refractory CNS Lymphoma Open
Purpose:Ibrutinib is a first-in-class inhibitor of Bruton tyrosine kinase. We previously reported the safety and short-term antitumor activity of ibrutinib in 20 patients with relapsed or refractory (r/r) primary central nervous system (CN…
View article: Supplementary Data 1 from A Phase II Study Assessing Long-term Response to Ibrutinib Monotherapy in Recurrent or Refractory CNS Lymphoma
Supplementary Data 1 from A Phase II Study Assessing Long-term Response to Ibrutinib Monotherapy in Recurrent or Refractory CNS Lymphoma Open
Additional data
View article: BMRK-11 REAL-WORLD EXPERIENCE WITH CIRCULATING TUMOR DNA IN CEREBROSPINAL FLUID IN PATIENTS WITH CENTRAL NERVOUS SYSTEM TUMORS
BMRK-11 REAL-WORLD EXPERIENCE WITH CIRCULATING TUMOR DNA IN CEREBROSPINAL FLUID IN PATIENTS WITH CENTRAL NERVOUS SYSTEM TUMORS Open
Next generation sequencing (NGS) of circulating tumor DNA (ctDNA) from cerebrospinal fluid (CSF) offers a minimally invasive approach to identify somatic alterations for individuals with central nervous system (CNS) cancers. Here, we revie…
View article: Maximizing the clinical utility and performance of cytology samples for comprehensive genetic profiling – A report on the impact of process optimization through the analysis of 4,871 cytology samples profiled by MSK-IMPACT
Maximizing the clinical utility and performance of cytology samples for comprehensive genetic profiling – A report on the impact of process optimization through the analysis of 4,871 cytology samples profiled by MSK-IMPACT Open
View article: Sharing Data from the Human Tumor Atlas Network through Standards, Infrastructure, and Community Engagement
Sharing Data from the Human Tumor Atlas Network through Standards, Infrastructure, and Community Engagement Open
The Data Coordinating Center (DCC) of the Human Tumor Atlas Network (HTAN) has played a crucial role in enabling the broad sharing and effective utilization of HTAN data within the scientific community. Data from the first phase of HTAN are …
View article: CEACAM5-Targeted Immuno-PET in Androgen Receptor–Negative Prostate Cancer
CEACAM5-Targeted Immuno-PET in Androgen Receptor–Negative Prostate Cancer Open
The incidence of androgen receptor (AR)-negative (AR-) prostate cancer, including aggressive neuroendocrine prostate cancer (NEPC), has more than doubled in the last decade, but its timely diagnosis is difficult as it lacks typi…
View article: Supplementary Table S5 from Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series
Supplementary Table S5 from Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series Open
Clinical, morphological and molecular features of MDA PCa PDXs pairs derived from the same patient
View article: Supplementary Table S6 from Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series
Supplementary Table S6 from Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series Open
STR Profiling of samples derived from the same patient
View article: Supplementary Figure S2 from Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series
Supplementary Figure S2 from Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series Open
General copy number profile and association with expresion for PTEN and RB1
View article: Supplementary Table S5 from Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series
Supplementary Table S5 from Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series Open
Clinical, morphological and molecular features of MDA PCa PDXs pairs derived from the same patient
View article: Supplementary Figure S2 from Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series
Supplementary Figure S2 from Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series Open
General copy number profile and association with expresion for PTEN and RB1
View article: Supplementary Figure S5 from Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series
Supplementary Figure S5 from Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series Open
CDK12 loss of function in MDA PCa PDX
View article: Supplementary Table S2 from Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series
Supplementary Table S2 from Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series Open
T200.1 panel: genes implicated in the pathogenesis of solid cancers
View article: Supplementary Table S3 from Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series
Supplementary Table S3 from Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series Open
Percentage of reads matching with mouse DNA
View article: Supplementary Table S1 from Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series
Supplementary Table S1 from Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series Open
Clinical and morphological features of 44 MDA PCa PDX
View article: Supplementary Figure S1 from Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series
Supplementary Figure S1 from Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series Open
MDA PCa PDX-derived organoids
View article: Supplementary Figure S4 from Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series
Supplementary Figure S4 from Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series Open
Detail of manually curated full or partial copy number/ transcript loss
View article: Supplementary Table S4 from Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series
Supplementary Table S4 from Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series Open
Fusions identified in MDA PCa PDX cohort
View article: Supplementary Table S4 from Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series
Supplementary Table S4 from Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series Open
Fusions identified in MDA PCa PDX cohort